Oncolytic immunotherapy for the treatment of non-muscle invasive bladder cancer using intravesical coxsackievirus A21
| Autor: | M. Denyer, Hugh Mostafid, Kevin J. Harrington, Attya Iqbal, Darren R. Shafren, Guy Simpson, Sarbjinder S Sandhu, Nicola E. Annels, Alan Melcher, Mehreen Arif, Hardev Pandha, David Mansfield, Gough G. Au, Mark Grose |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Pharmacology
Cancer Research Bladder cancer business.industry medicine.medical_treatment Bladder cancer cell Immunology Coxsackievirus A21 Immunotherapy medicine.disease Bioinformatics Oncolytic virus Oncology Poster Presentation Cancer research medicine Molecular Medicine Immunology and Allergy Non muscle invasive business |
| Zdroj: | Journal for Immunotherapy of Cancer |
| ISSN: | 2051-1426 |
| DOI: | 10.1186/2051-1426-3-s2-p331 |
| Popis: | Meeting abstracts As a clinical setting in which local live biological therapy is already well established, nonmuscle invasive bladder cancer (NMIBC) presents intriguing opportunities for oncolytic virotherapy. Coxsackievirus A21 (CVA21) is a novel intercellular adhesion molecule-1 (ICAM-1) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|